Drug and Medical Device Litigation

Expert Strategies for Leading Litigators & In-House Counsel

Thursday, June 29, 2006

About

The FDA's new Preemption Rule
New twists in ongoing COX-2 litigation
Device litigation and recalls

The stakes have never been higher…


The past year has had many watershed moments in drug and device litigation. The FDA-amidst ongoing turmoil-has boldly preempted state labeling laws through its rulemaking ability. COX-2 litigation continues to be waged; and there has been an unprecedented focus on device-related litigation.

The publication for ACI's Drug and Medical Device Litigation provides presentations that include:
  • The ramifications of the FDA's new preemption rule on the drug and device industries
  • Plaintiffs' latest theories – including procedural tactics, new twists on traditional causes of action, private civil liability claims, and the latest consumer protection actions
  • How to coordinate the defense in MDL claims
  • The foremost strategies for drug and device recalls
  • Best methods for controlling the corporate message and PR tactics
  • Cross-examination approaches to communicate critical information to your jury effectively
  • Contents & Contributors

    About

    The FDA's new Preemption Rule
    New twists in ongoing COX-2 litigation
    Device litigation and recalls

    The stakes have never been higher…


    The past year has had many watershed moments in drug and device litigation. The FDA-amidst ongoing turmoil-has boldly preempted state labeling laws through its rulemaking ability. COX-2 litigation continues to be waged; and there has been an unprecedented focus on device-related litigation.

    The publication for ACI's Drug and Medical Device Litigation provides presentations that include:
  • The ramifications of the FDA's new preemption rule on the drug and device industries
  • Plaintiffs' latest theories – including procedural tactics, new twists on traditional causes of action, private civil liability claims, and the latest consumer protection actions
  • How to coordinate the defense in MDL claims
  • The foremost strategies for drug and device recalls
  • Best methods for controlling the corporate message and PR tactics
  • Cross-examination approaches to communicate critical information to your jury effectively
  • Contents & Contributors


    FEDERAL PREEMPTION AND PRODUCT LABELING
    Daniel E. Troy, Sidley Austin Brown & Wood LLP

    EMPLOYING THE FDA REGULATORY PROCESS TO MINIMIZE PRODUCT LIABILITY RISKS

    Sandra J.P. Dennis, Morgan, Lewis & Bockius LLP
    FDA-RELATED ISSUES IN DRUG AND MEDICAL DEVICE LITIGATION
    Daniel J. Stephenson, Dykema Gossett PLLC
    Bryan J. Anderson, Dykema Gossett PLLC

    DRUG AND MEDICAL DEVICE LITIGATION: PREPARING FOR PLAINTIFF'S LATEST THEORIES: EMERGING CHALLENGES AND TARGETS OF MASS TORTS LITIGATION
    Peter L. Resnik, McDermott, Will & Emory

    PREPARING FOR PLAINTIFFS' LATEST THEORIES: CONSUMER FRAUD CLAIMS AND CHALLENGES TO CLINICAL TRIALS
    Vivian M. Quinn, Nixon Peabody LLP
    J. Christopher Allen, Jr., Nixon Peabody LLP

    RECENT TRENDS IN MEDICAL MONITORING CLAIMS IN MEDICAL DEVICE AND PHARMACEUTICAL CLASS ACTION LITIGATION
    Francis A. Citera, Greenberg Traurig LLP
    Edward M. Shin, Greenberg Traurig LLP

    THIRD PARTY PAYER SUITS: OBSERVATIONS FROM THE TOBACCO CASES
    Murray R. Garnick, Arnold & Porter LLP

    DEFENSE OF THIRD PARTY PAYOR PHARMACEUTICAL CASES
    Anthony Vale, Pepper Hamilton LLP

    STRUCTURING DEFENSE COUNSEL FOR PHARMACEUTICAL AND MEDICAL DEVICE MULTIDISTRICT LITIGATION
    J. Carter Thompson, Jr., Butler, Snow, O'Mara, Stevens & Cannada, PLLC
    William M. Gage, Butler, Snow, O'Mara, Stevens & Cannada, PLLC
    Lisa Martin, Butler, Snow, O'Mara, Stevens & Cannada, PLLC

    COORDINATING THE DEFENSE OF MDL CLAIMS: IMPORTANT CASE MANAGEMENT CONSIDERATION
    Stephen A. Wood, Kelley, Drye & Warren, LLP

    THE GUIDANT INDEPENDENT PANEL REPORT: IMPLICATIONS FOR THE MEDICAL DEVICE INDUSTRY
    Steven M. Kohn, Reed Smith, LLP
    Rosemary F. Luzon, Reed Smith, LLP

    POST-MARKETING EVENT REPORTS AND CLINICAL TRIAL DATA: POTENTIAL USES AND ABUSES IN LITIGATION
    Stephanie A. Scharf, Jenner & Block LLP

    ISSUES RELATED TO FOREIGNERS BRINGING PERSONAL INJURY, MASS TORT CLAIMS IN THE UNITED STATES
    Richard L. Berkman, Dechert LLP

    EFFECTIVELY MANAGING A MEDICAL DEVICE RECALL
    Robert Durgin, Biomet, Inc.

    HOW DO YOU DEFEND A PRODUCT THAT HAS BEEN RECALLED
    Connie Matteo, Porzio, Bromberg & Newman PC

    RECALL SYSTEM
    Thomas J. Stukane, Schering Plough Corporation
    CRISIS MANAGEMENT – CONTROLLING THE CORPORATE MESSAGE AND LIMITING NEGATIVE EXPOSURE
    Tanya J. Dobash, Taro Pharmaceuticals U.S.A., Inc.

    BERMUDA FORMS AND COVERAGE FOR DRUG AND MEDICAL DEVICE LIABILITY
    Richard P. Lewis, Anderson, Kill & Olick, P.C.

    INSURANCE COVERAGE CONUNDRUM – WORKING TOWARD A BETTER RELATIONSHIP
    Richard P. Lewis, Anderson, Kill & Olick, P.C.
    Cindy Khin, Insurance Operations Medmarc Insurance Group
    Lee Farrow, ACE Medical Risk

    THE ADMISSIBILITY OF EXPERT WITNESS TESTIMONY: DEBUNKING JUNK SCIENCE
    Randall L. Christian, Clark Thomas & Winters
    Harvey L. Kaplan, Shook, Hardy & Bacon, L.L.P

    . DIRECT TO CONSUMER ADVERTISING AND MEDICAL DEVICES
    Mark T. Piazza, Depuy Orthopaedics, Inc.

    DIRECT-TO-CONSUMER ADVERTISING AND THE LEARNED INTERMEDIARY DOCTRINE
    Daniel A. Kracov, Arnold & Porter, LLP



    DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0